TET2 and benign prostatic hyperplasia: This increased heterogeneity of genomic hydroxymethylation of WBC DNA, which also occurred in BPH and ASAP, may reflect the altered expression of genes that are involved in the cellular polarity pathway (e.g., BRSK2, STK11, FBF1) or in regulating TETs expression (e.g., TET1, TET2), as has been already described in prostate tumors [16,40].